Department of Clinical Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET.
Clin Endocrinol (Oxf). 2010 May;72(5):654-60. doi: 10.1111/j.1365-2265.2009.03685.x. Epub 2009 Aug 4.
Active acromegaly is associated with increased mortality from cardiovascular causes. Several studies have shown increased atherogenic risk factors and biomarkers of inflammation and atherosclerosis in association with growth hormone excess. The aim of this study was to evaluate oxidized low density lipoprotein (oxLDL) levels and some modulators of LDL oxidative modification in patients with acromegaly.
Open transversal study.
Fifteen patients with active acromegaly and 15 controls were studied.
We evaluated the levels of oxLDL, thiobarbituric acid reactive substances (TBARS), ceruloplasmin, bilirubin, uric acid and total reactive antioxidant potential, and the activities of ceruloplasmin, myeloperoxidase, superoxide distmutase, paraoxonase 1, and platelet activating factor acethylhydrolase. Statistical analysis was performed including body mass index as a covariate or as a fixed variable.
Patients with acromegaly showed significantly higher levels of oxLDL (120 +/- 19 vs. 86 +/- 20 U/l, P < 0.001) and endothelin (P < 0.05), increased ceruloplasmin activity (P < 0.01) and a trend towards higher values in TBARS concentration (P = 0.07) in comparison to healthy controls. OxLDL was positively associated with GH, IGF-I and its binding protein 3 (r = 0.63, P < 0.001; r = 0.53, P < 0.01; and r = 0.56, P < 0.01; respectively). OxLDL showed direct associations with endothelin-1 (r = 0.53, P < 0.01) and ceruloplasmin activity (r = 0.43, P < 0.05). The other parameters evaluated were similar in both groups.
The increase in plasma oxLDL levels, a direct marker of the plaque formation, could constitute a link between atherosclerosis and active acromegaly. LDL oxidation would not be the consequence of diminished antioxidant defences, but of an enhancement in prooxidant factors like ceruloplasmin.
活性肢端肥大症与心血管原因导致的死亡率增加有关。几项研究表明,生长激素过多与动脉粥样硬化的致动脉粥样硬化风险因素和炎症生物标志物增加有关。本研究旨在评估患有肢端肥大症患者的氧化低密度脂蛋白(oxLDL)水平和一些 LDL 氧化修饰的调节剂。
开放的横断研究。
15 名患有活性肢端肥大症的患者和 15 名对照者接受了研究。
我们评估了 oxLDL、硫代巴比妥酸反应物质(TBARS)、铜蓝蛋白、胆红素、尿酸和总反应性抗氧化能力,以及铜蓝蛋白、髓过氧化物酶、超氧化物歧化酶、对氧磷酶 1 和血小板激活因子乙酰水解酶的活性。进行了统计分析,包括体重指数作为协变量或固定变量。
肢端肥大症患者的 oxLDL 水平(120 ± 19 比 86 ± 20 U/L,P < 0.001)和内皮素(P < 0.05)显著升高,铜蓝蛋白活性升高(P < 0.01),TBARS 浓度呈升高趋势(P = 0.07)与健康对照组相比。oxLDL 与 GH、IGF-I 和其结合蛋白 3 呈正相关(r = 0.63,P < 0.001;r = 0.53,P < 0.01;r = 0.56,P < 0.01)。oxLDL 与内皮素-1(r = 0.53,P < 0.01)和铜蓝蛋白活性(r = 0.43,P < 0.05)呈直接相关。两组的其他参数相似。
血浆 oxLDL 水平的增加,斑块形成的直接标志物,可能是动脉粥样硬化和活性肢端肥大症之间的联系。LDL 氧化不是抗氧化防御减弱的结果,而是铜蓝蛋白等促氧化剂因素的增强。